PreludeDx™ Achieves New Milestones for DCIS Patients and DCISionRT® Testing

▤ Summary

PreludeDx highlights the growing adoption of its DCISionRT genomic test for women diagnosed with DCIS. The company says more than 3,000 physicians have ordered the test for over 45,000 patients, and usage continues to expand across academic and community cancer centers. The article also points to supporting clinical evidence, including studies showing the test can change radiation therapy recommendations and help guide personalized treatment decisions. Recent FDA Breakthrough Device and CMS ADLT designations strengthen the product’s clinical and commercial position.

▦ Linked Companies